SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, like Beta, exhibit increased immune evasion.
• Antibodies from individuals infected with or vaccinated against SARS-CoV-2 may show reduced efficacy against certain variants.

Purpose of the Study:

• To investigate the antibody response to the SARS-CoV-2 Beta variant.
• To isolate and characterize Beta-specific and cross-reactive antibodies from infected patients.
• To understand the impact of viral antigenic drift on antibody recognition.

Main Methods:

• Isolation and characterization of receptor-binding domain (RBD) antibodies from Beta-infected patients.
• Assessment of antibody neutralization against wild-type and variant SARS-CoV-2 strains.
• Analysis of genetic and structural features of identified antibodies.

Main Results:

• Serum from Beta-infected patients showed reduced cross-neutralization of the wild-type virus.
• Beta-specific and cross-reactive RBD antibodies were successfully isolated.
• Antibody specificity for Beta was linked to the recruitment of specific clonotypes and adaptation to mutations.
• Cross-reactive antibodies shared features with wild-type antibodies, including the VH1-58 clonotype targeting the RBD ridge.

Conclusions:

• The SARS-CoV-2 Beta variant elicits specific antibody responses that can accommodate viral mutations.
• Understanding these antibody dynamics is crucial for combating viral evolution.
• Findings have implications for designing next-generation vaccines and therapeutics against SARS-CoV-2 and future coronaviruses.